ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,051.09
      0.00%
      US Tech 100
      21,191.20
      0.62%
      Dow Jones
      43,828.06
      -0.20%
      Brent Oil
      74.135
      0.00%
      Bitcoin
      101,636.99
      0.18%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Biodesix Inc (BDSX) Quote

      Biodesix Inc

      Biodesix Inc (BDSX)

      NASDAQ
      1.34
      0.05
      (3.88%)
      Closed December 14 4:00PM
      Delayed by 15 minutes
      1.341
      0.001
      (0.07%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.34
      Bid
      1.19
      Ask
      1.39
      Volume
      223,491
      1.28 Day's Range 1.37
      1.11 52 Week Range 2.21
      Market Cap
      194.926M
      Previous Close
      1.29
      Open
      1.29
      Last Trade
      5
      @
      1.35
      Last Trade Time
      Financial Volume
      $ 295,849
      VWAP
      1.3238
      Average Volume (3m)
      452,156
      Shares Outstanding
      145,467,295
      Dividend Yield
      -
      PE Ratio
      -3.74
      Earnings Per Share (EPS)
      -0.36
      Revenue
      49.09M
      Net Profit
      -52.15M

      About Biodesix Inc

      Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic researc... Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Show more

      Sector
      Medical Laboratories
      Industry
      Medical Laboratories
      Website
      www.biodesix.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Biodesix Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker BDSX. The last closing price for Biodesix was $1.29. Over the last year, Biodesix shares have traded in a share price range of $ 1.11 to $ 2.21.

      Biodesix currently has 145,467,295 shares outstanding. The market capitalization of Biodesix is $187.65 million. Biodesix has a price to earnings ratio (PE ratio) of -3.74.

      Ask ADVFN Intelligence (AI)

      BDSX Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      November 22 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 13 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 13 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 13 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 13 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 13 2024
      Edgar (US Regulatory)

      Form EFFECT - Notice of Effectiveness

      November 13 2024
      Edgar (US Regulatory)

      Form EFFECT - Notice of Effectiveness

      November 13 2024
      Edgar (US Regulatory)

      Form 424B3 - Prospectus [Rule 424(b)(3)]

      November 12 2024
      Edgar (US Regulatory)

      Form 424B5 - Prospectus [Rule 424(b)(5)]

      November 12 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.032.290076335881.311.391.242867551.32739185CS
      4-0.04-2.898550724641.381.51.117284361.26227373CS
      12-0.45-25.13966480451.791.851.114521561.38003297CS
      26-0.19-12.41830065361.532.041.112846771.45402051CS
      52-0.22-14.10256410261.562.211.112119361.49855782CS
      156-3.52-72.42798353914.865.99730.9551945721.82763981CS
      260-12.25-90.139808682913.5931.990.9551765614.30632929CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WKEYWISeKey International Holdings AG
      $ 7.84
      (139.02%)
      		75.53M
      IPHAInnate Pharma SA
      $ 3.00
      (93.55%)
      		13.59M
      AVLDirexion Daily AVGO Bull 2X Shares
      $ 33.67
      (48.92%)
      		658.55k
      LOOPLoop Industries Inc
      $ 1.8092
      (47.09%)
      		82.56M
      AVGXDefiance Daily Target 2X Long AVGO ETF
      $ 31.49
      (46.67%)
      		3.55M
      RPTXRepare Therapeutics Inc
      $ 1.765
      (-55.54%)
      		4.59M
      INOInovio Pharmaceuticals Inc New
      $ 2.31
      (-38.56%)
      		9.59M
      XXII22nd Century Group Inc
      $ 0.048
      (-34.69%)
      		41.72M
      FLGCFlora Growth Corporation
      $ 1.30
      (-34.34%)
      		4.01M
      WTOUTime Limited
      $ 0.281
      (-32.74%)
      		3.79M
      NVDANVIDIA Corporation
      $ 134.25
      (-2.25%)
      		228.17M
      SOUNSoundHound AI Inc
      $ 16.905
      (23.66%)
      		158.74M
      TRUGTruGolf Holdings Inc
      $ 0.6794
      (30.93%)
      		138.19M
      RGTIRigetti Computing Inc
      $ 7.155
      (19.85%)
      		122.67M
      AVGOBroadcom Inc
      $ 224.80
      (24.43%)
      		117.74M

      BDSX Discussion

      View Posts
      PonkenPlonken PonkenPlonken 1 week ago
      Mr Schuler is buying shares again
      👍️0
      tw0122 tw0122 1 month ago
      Is selling $250 million in stock fro time to time on the downside.. Separately, Biodesix filed a registration statement to sell up to $250 million in securities from time to time.
      👍️0
      tw0122 tw0122 1 month ago
      Lung diagnostics cancer revenues improving still has $33m cash $1.49 +'14%
      👍️0
      AJ Freely AJ Freely 1 year ago
      $BDSX - Up 12%/ Current Price $1.34.
      Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
      👍️0
      1hot toddy 1hot toddy 2 years ago
      WOOOOOOW 130K SHARES BUY NOW 2.6 MIL SHARE BUY $

      3 MILLION $ BUY $$$$$$$$$$$$$$$$$$$$$$
      👍️0
      Leg58 Leg58 2 years ago
      Lots if potential but will public offering dilute price?
      👍️0
      Leg58 Leg58 2 years ago
      Lots if potential but will public offering dilute price?
      👍️0
      subslover subslover 2 years ago
      Earnings look good.
      👍️0
      subslover subslover 2 years ago
      Earnings look good.
      👍️0
      MiamiGent MiamiGent 2 years ago
      BDSX Has news this morning!

      The contract covers the company’s entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS™ testing.

      https://investors.biodesix.com/news-releases/news-release-details/biodesix-awarded-us-federal-supply-schedule-contract-its

      https://stockcharts.com/h-sc/ui?s=BDSX
      👍️0
      carusso carusso 2 years ago
      Not so much...
      👍️0
      crudeoil24 crudeoil24 2 years ago
      LET'S GO BDSX !!!!!
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Biodesix to Participate in Two Upcoming Investor Conferences in September
      6:00 am ET September 6, 2022 (BusinessWire) Print
      Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

      Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.

      H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings Location: Lotte New York Palace Hotel, New York, NY
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
      👍️0
      Leg58 Leg58 2 years ago
      US based company is quietly trending up. IMHO.
      GLTA
      👍️0

      Your Recent History

      NASDAQ
      BDSX
      Biodesix
      Delayed Upgrade Clock